Sarah Ford | November 20, 2014
Drug Restores Memory Function in Alzheimer’s Model
Building on earlier work funded by BrightFocus, researchers have discovered a promising new drug compound that reverses some
Alzheimer’s effects on memory in mice.
Four years ago, a research team led by BrightFocus grantee and Nobel Laureate Dr. Paul Greengard established the connection between increased striatal-enriched tyrosine phosphatase (STEP) levels and Alzheimer’s changes in mice, and showed that removing STEP had the effect of restoring synaptic connections.
Since their discovery of STEP, this research team has been searching for a drug that would block its damaging effects on brain synapses. They focused their efforts on finding a STEP inhibitor, studying thousands of small molecules in their quest.
Get Resources and Insights Straight To Your Inbox
Explore More Articles
Before the Storm: A Different Way to Think About Corporate Disaster Giving
Featured on Bright Harbor with insights from our CEO Jim Starr. Ask any corporate giving officer what their disaster response strategy looks like and you’ll…
Emergency Assistance Funds: Corporate Responsibility Begins at Home
The Hard Truth: Employee Financial Stress Directly Impacts the Workplace Approximately 2 in 5 Americans, or 37%, say they could not afford an emergency expense…
America’s Charities Named ‘Best Nonprofit To Work For’ For Sixth Consecutive Year
Washington, D.C. – April 1, 2026 – America’s Charities, a nonprofit dedicated to mobilizing the power of giving through workplace and employee engagement solutions, today…
Get Resources and Insights Straight To Your Inbox
Receive our monthly/bi-monthly newsletter filled with information about causes, nonprofit impact, and topics important for corporate social responsibility and employee engagement professionals, including disaster response, workplace giving, matching gifts, employee assistance funds, volunteering, scholarship award program management, grantmaking, and other philanthropic initiatives.
